Is Phathom Pharmaceuticals, Inc. (PHAT) a Buy, Sell, or Hold?
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$10.79 USD
-$0.24 (-2.22%)
- Volume
- 484.71K
- Average Volume
- 1.24M
- Market Capitalization
- $860.57M
- P/E Ratio
- -5.09
- Dividend Yield
- 0.00%
- Price Target
- $23.00
- Year High
- $18.31
- Year Low
- $7.61
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.21
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Steven L. Basta |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | PHAT |
| CUSIP | 71722W107 |
| CIK | 0001783183 |
| Web | https://www.phathompharma.com |
| Phone | 877 742 8466 |
| Currency | USD |
| Employees | 371 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.49 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.21 |
| Quick Ratio | 2.16 |
| Cash Ratio | 1.45 |
Sales & Book Value
| Annual Sales | $175.11M |
| Price / Sales | 4.20 |
| Cash Flow | -1.19 |
| Price / Cash Flow | -8.84 |
| Price / Book | -2.63 |
Price Target and Rating
| Average Stock Price Forecast | $23.00 |
| High Stock Price Forecast | $28.00 |
| Low Stock Price Forecast | $18.00 |
| Forecast Upside/Downside | -53.09% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.03 |
| Trailing P/E Ratio | -5.09 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | $-221.25M |
| Net Margin | -76.77% |
| Pretax Margin | -76.77% |
| Return on Equity | 39.24% |
| Return on Assets | -51.55% |
Financials Score
| AltmanZ Score | -5.86 |
| Piotroski Score | 3.00 |
| Working Capital | 151.53M |
| Total Assets | 305.12M |
| Ebit | -91.46M |
| Market Cap | 870.54M |
| Total Liabilities | 642.08M |
Poll Results
About Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey. ...
2026-06-23 07:59:00
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 of 2026 FLORHAM PARK, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults.
2026-06-09 17:12:11
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-22 08:00:00
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in May and June:
2026-05-20 08:00:00
FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today highlighted the growing body of clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA® (vonoprazan), at Digestive Disease Week (DDW) 2026, held May 2–5, 2026 in Chicago, Illinois. Phathom presented three posters at the meeting, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study that was recognized by DDW as a Poster of Distinction, a designation reserved for abstracts of notable scientific merit. Vonoprazan was also the subject of 28 additional independent, investigator-initiated abstracts across gastroesophageal reflux disease (GERD), Helicobacter pylori (H. pylori) eradication, long-term safety, and post endoscopic procedural care, reflecting the growing scientific interest in vonoprazan and the potassium-competitive acid blocker (PCAB) class in GI medicine.
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
2026-05-01 08:00:00
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week® (DDW) 2026 annual meeting, being held May 2–5 in Chicago, Illinois.
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
2026-04-30 15:31:44
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
2026-04-30 09:35:16
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $1.07 per share a year ago.
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-30 06:59:00
FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Frequently Asked Questions
-
What is the current Phathom Pharmaceuticals, Inc. (PHAT) stock price?
-
Phathom Pharmaceuticals, Inc.(NASDAQ:PHAT) stock price is $10.79 in the last trading session. During the trading session, PHAT stock reached the peak price of $18.31 while $7.61 was the lowest point it dropped to. The percentage change in PHAT stock occurred in the recent session was --2.22% while the dollar amount for the price change in PHAT stock was -$-0.24.
-
PHAT's industry and sector of operation?
-
The NASDAQ listed PHAT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PHAT?
-
Anne Marie Cook | Chief Legal Officer & Corporate Secretary
Nancy R. Phelan | Senior Vice President of Marketing & Analytics
Steven L. Basta | Chief Executive Officer, President & Director
Paul Cocja | Chief People Officer
Robert Breedlove | Vice President of Finance & Principal Accounting Officer -
How many employees does PHAT have?
-
Number of PHAT employees currently stands at 371. PHAT operates from 100 Campus Drive, Florham Park, NJ 07932, US.
-
Link for PHAT official website?
-
Official Website of PHAT is: https://www.phathompharma.com
-
How do I contact PHAT?
-
PHAT could be contacted at phone #877 742 8466 and can also be accessed through its website. PHAT operates from 100 Campus Drive, Florham Park, NJ 07932, US.
-
How many shares of PHAT are traded daily?
-
The average number of PHAT shares traded daily for last 3 months was 1.24M.
-
What is the market cap of PHAT currently?
-
The market value of PHAT currently stands at $860.57M with its latest stock price at $10.79